You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. RFA-ES-22-006: New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)

    Release Date: 06-30-2022Open Date: 10-08-2022Due Date: 11-08-2022Close Date: 11-09-2022

    This FOA solicits Phase I (R43), Phase II, Direct to Phase II (R44) and Fast-track (R44) SBIR grant applications from SBCs to develop resources and approaches that reflect the variability in responses to chemical exposures based on genetic diversity in the human population. These can include panels of human cells or cell lines, rodent panels, including cell lines generated from rodent diversity pa ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. RFA-DK-21-011: Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)

    Release Date: 05-06-2021Open Date: 02-09-2022 Due Dates: Multiple Close Date: 10-08-2022

    Despite the availability of increasingly effective treatment modalities, including insulin analogues, continuous glucose monitors (CGMs), and continuous subcutaneous insulin infusion (CSII) devices, a substantial proportion of patients with type 1 diabetes (T1D) cannot achieve adequate glycemic control and avoid acute complications such as hypoglycemia. NIDDK has long supported this area of resear ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. RFA-DK-21-012: Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

    Release Date: 05-19-2021Open Date: 02-09-2022 Due Dates: Multiple Close Date: 10-08-2022

    Despite clear progress made during the last 15 years on cellular transplantation for T1D, the most recent results demonstrate a long-term limited viability of engrafted islets and, as a result, limited insulin independence under different novel modalities of immunosuppressive (IS) regimens tested. In addition, even the most innovative IS regimens required for transplant survival still have signifi ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. RFA-DK-21-021: Support for Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

    Release Date: 06-25-2021Open Date: 01-17-2022 Due Dates: Multiple Close Date: 10-07-2022

    Early identification of T1D risk and the onset of autoimmunity provides the basis for a variety of major ongoing studies seeking to prevent or delay the disease. Ongoing research on the natural history of the development of T1D in at risk neonates has shown that early identification of those at risk can foster early diagnosis of T1D and avoid life-threatening diabetic ketoacidosis (DKA). It is est ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. HHS-2022-ACL-NIDILRR-BISA-0019: Small Business Innovation Research (SBIR) program, Phase I

    Release Date: 11-19-2021Open Date: 11-19-2021Due Date: 01-18-2022Close Date: 09-30-2022

    NIDILRR’s mission is to generate new knowledge and to promote its effective use to improve the abilities of individuals with disabilities to perform activities of their choice in the community and to expand society’s capacity to provide full opportunities and accommodations for its citizens with disabilities. All SBIR projects funded by NIDILRR must address the needs of individuals with disabi ...

    SBIRPhase IDepartment of Health and Human ServicesAdministration for Community Living
  6. RFA-NS-20-008 : HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Required)

    Release Date: 10-04-2019Open Date: 12-08-2019 Due Dates: Multiple Close Date: 09-08-2022

    Purpose The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. Specifically, this FOA is focused on applications directed at improving pain measurement ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. RFA-NS-20-009 : RFA-NS-20-009

    Release Date: 10-03-2019Open Date: 12-08-2019 Due Dates: Multiple Close Date: 09-08-2022

    Purpose The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. Specifically, this FOA is focused on applications directed at improving pain measurement ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. RFA-NS-20-010 : HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44- Clinical Trial Required)

    Release Date: 10-04-2019Open Date: 12-08-2019 Due Dates: Multiple Close Date: 09-08-2022

    Purpose The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. Specifically, this FOA is focused on applications directed at improving pain measurement ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. RFA-NS-20-011 : RFA-NS-20-011

    Release Date: 10-01-2019Open Date: 12-08-2019 Due Dates: Multiple Close Date: 09-08-2022

    Purpose The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. Specifically, this FOA is focused on applications directed at improving pain measurement ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. PAR-21-030: Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)

    Release Date: 10-08-2020Open Date: 12-05-2020 Due Dates: Multiple Close Date: 09-06-2022

    Purpose This Funding Opportunity Announcement (FOA) encourages the translation of technology and therapeutic innovations from academic and other non-profit research sectors to the marketplace to advance the development of diagnostic and prevention tools or treatments for musculoskeletal, rheumatic or skin diseases. Small Business Concerns (SBCs) are encouraged to apply for this Small Business Inn ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government